Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Theodore P Nicolaides

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 12, 2017
Inhibiting 4EBP1 in GlioblastomaQi Wen Fan, Theodore P Nicolaides, William A Weiss
Pediatric Blood & Cancer|January 31, 2004
High-dose chemotherapy with autologous stem-cell rescue in the treatment of patients with recurrent non-cerebellar primitive neuroectodermal tumorsAlberto Broniscer, Theodore P Nicolaides, Ira J Dunkel, et al.
Cancer Research|September 7, 2007
A dual phosphoinositide-3-kinase alpha/mTOR inhibitor cooperates with blockade of epidermal growth factor receptor in PTEN-mutant gliomaQi-Wen Fan, Christine K Cheng, Theodore P Nicolaides, et al.
Cancer Research|May 13, 2010
Intratumoral therapy of glioblastoma multiforme using genetically engineered transferrin for drug deliveryDennis J Yoon, Byron H Kwan, Felix C Chao, et al.
Nanomaterials (Basel, Switzerland)|December 20, 2018
Evaluation of Three Morphologically Distinct Virus-Like Particles as Nanocarriers for Convection-Enhanced Drug Delivery to GlioblastomaJoel A Finbloom, Ioana L Aanei, Jenna M Bernard, et al.
Oncotarget|October 8, 2016
Concurrent MEK targeted therapy prevents MAPK pathway reactivation during BRAFV600E targeted inhibition in a novel syngeneic murine glioma modelStefan Grossauer, Katharina Koeck, Nicole E Murphy, et al.
Journal of Neuro-Oncology|September 20, 2015
Survival advantage combining a BRAF inhibitor and radiation in BRAF V600E-mutant gliomaTina Dasgupta, Aleksandra K Olow, Xiaodong Yang, et al.
Cell Reports|August 22, 2019
Driving Neuronal Differentiation through Reversal of an ERK1/2-miR-124-SOX9 Axis Abrogates Glioblastoma AggressivenessHanna Sabelström, Rebecca Petri, Ksenya Shchors, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 1, 2011
Targeted therapy for BRAFV600E malignant astrocytomaTheodore P Nicolaides, Huifang Li, David A Solomon, et al.
The Journal of Clinical Investigation|August 13, 2024
Pediatric glioma immune profiling identifies TIM3 as a therapeutic target in BRAF fusion pilocytic astrocytomaShashwat Tripathi, Hinda Najem, Corey Dussold, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 12, 2017
Inhibiting 4EBP1 in GlioblastomaQi Wen Fan, Theodore P Nicolaides, William A Weiss
Pediatric Blood & Cancer|January 31, 2004
High-dose chemotherapy with autologous stem-cell rescue in the treatment of patients with recurrent non-cerebellar primitive neuroectodermal tumorsAlberto Broniscer, Theodore P Nicolaides, Ira J Dunkel, et al.
Cancer Research|September 7, 2007
A dual phosphoinositide-3-kinase alpha/mTOR inhibitor cooperates with blockade of epidermal growth factor receptor in PTEN-mutant gliomaQi-Wen Fan, Christine K Cheng, Theodore P Nicolaides, et al.
Cancer Research|May 13, 2010
Intratumoral therapy of glioblastoma multiforme using genetically engineered transferrin for drug deliveryDennis J Yoon, Byron H Kwan, Felix C Chao, et al.
Nanomaterials (Basel, Switzerland)|December 20, 2018
Evaluation of Three Morphologically Distinct Virus-Like Particles as Nanocarriers for Convection-Enhanced Drug Delivery to GlioblastomaJoel A Finbloom, Ioana L Aanei, Jenna M Bernard, et al.
Oncotarget|October 8, 2016
Concurrent MEK targeted therapy prevents MAPK pathway reactivation during BRAFV600E targeted inhibition in a novel syngeneic murine glioma modelStefan Grossauer, Katharina Koeck, Nicole E Murphy, et al.
Journal of Neuro-Oncology|September 20, 2015
Survival advantage combining a BRAF inhibitor and radiation in BRAF V600E-mutant gliomaTina Dasgupta, Aleksandra K Olow, Xiaodong Yang, et al.
Cell Reports|August 22, 2019
Driving Neuronal Differentiation through Reversal of an ERK1/2-miR-124-SOX9 Axis Abrogates Glioblastoma AggressivenessHanna Sabelström, Rebecca Petri, Ksenya Shchors, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 1, 2011
Targeted therapy for BRAFV600E malignant astrocytomaTheodore P Nicolaides, Huifang Li, David A Solomon, et al.
The Journal of Clinical Investigation|August 13, 2024
Pediatric glioma immune profiling identifies TIM3 as a therapeutic target in BRAF fusion pilocytic astrocytomaShashwat Tripathi, Hinda Najem, Corey Dussold, et al.
Pageof 2